Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Osteoporosis International
Published in: Osteoporosis International 4/2016

01-04-2016 | Review Article

Fracture risk and bone mineral density levels in patients with systemic lupus erythematosus: a systematic review and meta-analysis

Authors: X. Wang, S. Yan, C. Liu, Y. Xu, L. Wan, Y. Wang, W. Gao, S. Meng, Y. Liu, R. Liu, D. Xu

Published in: Osteoporosis International | Issue 4/2016

Login to get access

Abstract

Previous studies suggested possible bone loss and fracture risk in patients with systemic lupus erythematosus (SLE). The aim of this systematic review and meta-analysis was to assess the strength of the relationship of SLE with fracture risk and the mean difference of bone mineral density (BMD) levels between SLE patients and controls. Literature search was undertaken in multiple indexing databases on September 26, 2015. Studies on the relationship of SLE with fracture risk and the mean difference of BMD levels between SLE patients and controls were included. Data were combined using standard methods of meta-analysis. Twenty-one studies were finally included into the meta-analysis, including 15 studies on the mean difference of BMD levels between SLE patients and controls, and 6 studies were on fracture risk associated with SLE. The meta-analysis showed that SLE patients had significantly lower BMD levels than controls in the whole body (weighted mean difference [WMD] = −0.04; 95 % CI −0.06 to −0.02; P < 0.001), femoral neck (WMD = −0.06; 95 % CI −0.07 to −0.04; P < 0.001), lumbar spine (WMD = −0.06; 95 % CI −0.09 to −0.03; P < 0.001), and total hip (WMD = −0.05; 95 % CI −0.06 to −0.03; P < 0.001). In addition, the meta-analysis also showed that SLE was significantly associated with increased fracture risk of all sites (relative risk [RR] = 1.97, 95 % CI 1.20–3.25; P = 0.008). Subgroup analysis by adjustment showed that SLE was significantly associated with increased fracture risk of all sites before and after adjusting for confounding factors (unadjusted RR = 2.07, 95 % CI 1.46–2.94, P < 0.001; adjusted RR = 1.22, 95 % CI 1.05–1.42, P = 0.01). Subgroup analysis by types of fracture showed that SLE was significantly associated with increased risks of hip fracture (RR = 1.99, 95 % CI 1.55–2.57; P < 0.001), osteoporotic fracture (RR = 1.36, 95 % CI 1.21–1.53; P < 0.001), and vertebral fracture (RR = 2.97, 95 % CI 1.71–5.16; P < 0.001). This systematic review and meta-analysis provides strong evidence for the relationship of SLE with bone loss and fracture risk.
Literature
1.
Panopalis P, Yazdany J (2009) Bone health in systemic lupus erythematosus. Curr Rheumatol Rep 11(3):177–184CrossRefPubMed
2.
Mohan C, Putterman C (2015) Genetics and pathogenesis of systemic lupus erythematosus and lupus nephritis. Nat Rev Nephrol 11(6):329–341CrossRefPubMed
3.
Lisnevskaia L, Murphy G, Isenberg D (2014) Systemic lupus erythematosus. Lancet 384(9957):1878–1888CrossRefPubMed
4.
Leffler J, Bengtsson AA, Blom AM (2014) The complement system in systemic lupus erythematosus: an update. Ann Rheum Dis 73(9):1601–1606CrossRefPubMed
5.
Merrill JT, Buyon JP, Utset T (2014) A 2014 update on the management of patients with systemic lupus erythematosus. Semin Arthritis Rheum 44(2):e1–e2CrossRefPubMed
6.
Wallace DJ (2015) The evolution of drug discovery in systemic lupus erythematosus. Nat Rev Rheumatol 11(10):616–620CrossRefPubMed
7.
Lupsa BC, Insogna K (2015) Bone health and osteoporosis. Endocrinol Metab Clin N Am 44(3):517–530CrossRef
8.
Drake MT, Clarke BL, Lewiecki EM (2015) The pathophysiology and treatment of osteoporosis. Clin Ther 37(8):1837–1850CrossRefPubMed
9.
Reid IR (2015) Short-term and long-term effects of osteoporosis therapies. Nat Rev Endocrinol 11(7):418–428CrossRefPubMed
10.
Golob AL, Laya MB (2015) Osteoporosis: screening, prevention, and management. Med Clin N Am 99(3):587–606CrossRefPubMed
11.
Bultink IE, Harvey NC, Lalmohamed A, Cooper C, Lems WF, van Staa TP, de Vries F (2014) Elevated risk of clinical fractures and associated risk factors in patients with systemic lupus erythematosus versus matched controls: a population-based study in the United Kingdom. Osteoporos Int 25(4):1275–1283CrossRefPubMed
12.
Tang XL, Qin L, Kwok AW, Zhu TY, Kun EW, Hung VW, Griffith JF, Leung PC, Li EK, Tam LS (2013) Alterations of bone geometry, density, microarchitecture, and biomechanical properties in systemic lupus erythematosus on long-term glucocorticoid: a case-control study using HR-pQCT. Osteoporos Int 24(6):1817–1826CrossRefPubMed
13.
Furukawa M, Kiyohara C, Horiuchi T, Tsukamoto H, Mitoma H, Kimoto Y, Uchino A, Nakagawa M, Oryoji K, Shimoda T et al (2013) Prevalence and risk factors of vertebral fracture in female Japanese patients with systemic lupus erythematosus. Mod Rheumatol 23(4):765–773CrossRefPubMed
14.
Bultink IE (2012) Osteoporosis and fractures in systemic lupus erythematosus. Arthritis Care Res 64(1):2–8CrossRef
15.
Ajeganova S, Gustafsson T, Jogestrand T, Frostegard J, Hafstrom I (2015) Bone mineral density and carotid atherosclerosis in systemic lupus erythematosus: a controlled cross-sectional study. Arthritis Res Ther 17(84)
16.
Tang XL, Griffith JF, Qin L, Hung VW, Kwok AW, Zhu TY, Kun EW, Leung PC, Li EK, Tam LS (2013) SLE disease per se contributes to deterioration in bone mineral density, microstructure and bone strength. Lupus 22(11):1162–1168CrossRefPubMed
17.
Casella CB, Seguro LP, Takayama L, Medeiros D, Bonfa E, Pereira RM (2012) Juvenile onset systemic lupus erythematosus: a possible role for vitamin D in disease status and bone health. Lupus 21(12):1335–1342CrossRefPubMed
18.
Mok CC, Ying SK, To CH, Ma KM (2008) Bone mineral density and body composition in men with systemic lupus erythematosus: a case control study. Bone 43(2):327–331CrossRefPubMed
19.
Borba VZ, Matos PG, da Silva Viana PR, Fernandes A, Sato EI, Lazaretti-Castro M (2005) High prevalence of vertebral deformity in premenopausal systemic lupus erythematosus patients. Lupus 14(7):529–533CrossRefPubMed
20.
Formiga F, Nolla JM, Mitjavila F, Bonnin R, Navarro MA, Moga I (1996) Bone mineral density and hormonal status in men with systemic lupus erythematosus. Lupus 5(6):623–626CrossRefPubMed
21.
Bonfa AC, Seguro LP, Caparbo V, Bonfa E, Pereira RM (2015) RANKL and OPG gene polymorphisms: associations with vertebral fractures and bone mineral density in premenopausal systemic lupus erythematosus. Osteoporos Int 26(5):1563–1571CrossRefPubMed
22.
Liyanage A, Lekamwasam S, Dissanayake SP, Munidasa D (2013) Factors that determine body composition of female systemic lupus erythematosus (SLE) patients in Sri Lanka: a comparative study using dual-energy x-ray absorptiometry. Lupus 22(9):972–976CrossRefPubMed
23.
24.
Wang SH, Chang YS, Liu CJ, Lai CC, Chen WS, Chen TJ, Wang SJ (2013) Association of systemic lupus erythematosus with a higher risk of cervical but not trochanteric hip fracture: a nationwide population-based study. Arthritis Care Res 65(10):1674–1681
25.
Ekblom-Kullberg S, Kautiainen H, Alha P, Leirisalo-Repo M, Julkunen H (2013) Frequency of and risk factors for symptomatic bone fractures in patients with systemic lupus erythematosus. Scand J Rheumatol 42(5):390–393CrossRefPubMed
26.
Hippisley-Cox J, Coupland C (2012) Derivation and validation of updated QFracture algorithm to predict risk of osteoporotic fracture in primary care in the United Kingdom: prospective open cohort study. BMJ 344, e3427CrossRefPubMed
27.
Weiss RJ, Wick MC, Ackermann PW, Montgomery SM (2010) Increased fracture risk in patients with rheumatic disorders and other inflammatory diseases—a case-control study with 53,108 patients with fracture. J Rheumatol 37(11):2247–2250CrossRefPubMed
28.
Mendoza-Pinto C, Garcia-Carrasco M, Sandoval-Cruz H, Munoz-Guarneros M, Escarcega RO, Jimenez-Hernandez M, Munguia-Realpozo P, Sandoval-Cruz M, Deleze-Hinojosa M, Lopez-Colombo A et al (2009) Risk factors of vertebral fractures in women with systemic lupus erythematosus. Clin Rheumatol 28(5):579–585CrossRefPubMed
29.
Li EK, Tam LS, Griffith JF, Zhu TY, Li TK, Li M, Wong KC, Chan M, Lam CW, Chu FS et al (2009) High prevalence of asymptomatic vertebral fractures in Chinese women with systemic lupus erythematosus. J Rheumatol 36(8):1646–1652CrossRefPubMed
30.
Yee CS, Crabtree N, Skan J, Amft N, Bowman S, Situnayake D, Gordon C (2005) Prevalence and predictors of fragility fractures in systemic lupus erythematosus. Ann Rheum Dis 64(1):111–113CrossRefPubMedPubMedCentral
31.
Stang A (2010) Critical evaluation of the Newcastle-Ottawa Scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25(9):603–605CrossRefPubMed
32.
Higgins JPT, Green S (2011) Cochrane Handbook for Systematic Reviews of Interventions. In: Higgins JP, Green S (eds). The Cochrane Collaboration
33.
Cochran WG (1954) The combination of estimates from different experiments. Biometrics 10(1):101–129CrossRef
34.
35.
Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22(4):719–748PubMed
36.
37.
38.
Trapani S, Civinini R, Ermini M, Paci E, Falcini F (1998) Osteoporosis in juvenile systemic lupus erythematosus: a longitudinal study on the effect of steroids on bone mineral density. Rheumatol Int 18(2):45–49CrossRefPubMed
39.
Teichmann J, Lange U, Stracke H, Federlin K, Bretzel RG (1999) Bone metabolism and bone mineral density of systemic lupus erythematosus at the time of diagnosis. Rheumatol Int 18(4):137–140CrossRefPubMed
40.
Mak A, Lim JQ, Liu Y, Cheak AA, Ho RC (2013) Significantly higher estimated 10-year probability of fracture in lupus patients with bone mineral density comparable to that of healthy individuals. Rheumatol Int 33(2):299–307CrossRefPubMed
41.
Hansen S, Gudex C, Ahrberg F, Brixen K, Voss A (2014) Bone geometry, volumetric bone mineral density, microarchitecture and estimated bone strength in Caucasian females with systemic lupus erythematosus. A cross-sectional study using HR-pQCT. Calcif Tissue Int 95(6):530–539CrossRefPubMed
42.
Abdwani R, Abdulla E, Yaroubi S, Bererhi H, Al-Zakwani I (2015) Bone mineral density in juvenile onset systemic lupus erythematosus. Indian Pediatr 52(1):38–40CrossRefPubMed
43.
Rhew EY, Lee C, Eksarko P, Dyer AR, Tily H, Spies S, Pope RM, Ramsey-Goldman R (2008) Homocysteine, bone mineral density, and fracture risk over 2 years of followup in women with and without systemic lupus erythematosus. J Rheumatol 35(2):230–236PubMed
44.
Schmajuk G, Yelin E, Chakravarty E, Nelson LM, Panopolis P, Yazdany J (2010) Osteoporosis screening, prevention, and treatment in systemic lupus erythematosus: application of the systemic lupus erythematosus quality indicators. Arthritis Care Res 62(7):993–1001CrossRef
45.
Garcia-Carrasco M, Mendoza-Pinto C, Escarcega RO, Jimenez-Hernandez M, Etchegaray Morales I, Munguia Realpozo P, Rebollo-Vazquez J, Soto-Vega E, Deleze M, Cervera R (2009) Osteoporosis in patients with systemic lupus erythematosus. Isr Med Assoc J 11(8):486–491PubMed
46.
Pineau CA, Urowitz MB, Fortin PJ, Ibanez D, Gladman DD (2004) Osteoporosis in systemic lupus erythematosus: factors associated with referral for bone mineral density studies, prevalence of osteoporosis and factors associated with reduced bone density. Lupus 13(6):436–441CrossRefPubMed
47.
Becker A, Fischer R, Scherbaum WA, Schneider M (2001) Osteoporosis screening in systemic lupus erythematosus: impact of disease duration and organ damage. Lupus 10(11):809–814CrossRefPubMed
48.
Straub RH, Cutolo M, Pacifici R (2015) Evolutionary medicine and bone loss in chronic inflammatory diseases—A theory of inflammation-related osteopenia. Semin Arthritis Rheum 45(2):220–228CrossRefPubMedPubMedCentral
49.
von Scheven E, Corbin KJ, Stagi S, Cimaz R (2014) Glucocorticoid-associated osteoporosis in chronic inflammatory diseases: epidemiology, mechanisms, diagnosis, and treatment. Curr Osteoporos Rep 12(3):289–299CrossRef
50.
Sundstrom J, Arima H, Woodward M, Jackson R, Karmali K, Lloyd-Jones D, Baigent C, Emberson J, Rahimi K, MacMahon S et al (2014) Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet 384(9943):591–598CrossRef
Metadata
Title
Fracture risk and bone mineral density levels in patients with systemic lupus erythematosus: a systematic review and meta-analysis
Authors
X. Wang
S. Yan
C. Liu
Y. Xu
L. Wan
Y. Wang
W. Gao
S. Meng
Y. Liu
R. Liu
D. Xu
Publication date
01-04-2016
Publisher
Springer London
Published in
Osteoporosis International / Issue 4/2016
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-015-3449-7

Other articles of this Issue 4/2016

Osteoporosis International 4/2016 Go to the issue

Review

Osteoporosis in the adult solid organ transplant population: underlying mechanisms and available treatment options

Original Article

Serum carcinoembryonic antigen-related cell adhesion molecule 1 level in postmenopausal women: correlation with β-catenin and bone mineral density

Letter

Proton pump inhibitors and fracture risk: response to comments

Short Communication

Central and peripheral fat body mass have a protective effect on osteopenia or osteoporosis in adults and elderly?

Original Article

Osteoporosis in adults with cerebral palsy: feasibility of DXA screening and risk factors for low bone density

Original Article

Bone material strength is associated with areal BMD but not with prevalent fractures in older women